Physician profile
Thomas S Wind
NPI 1508982265
$17,307.25
in general payments reported to CMS, 2019-2025
34 companies · $2,659 in 2025
The $2,659 reported for 2025 was more than what 95% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $933 · 2020: $1,811 · 2021: $2,385 · 2022: $2,851 · 2023: $3,747 · 2024: $2,921 · 2025: $2,659.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,327.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,326.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,415.13 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,103.65 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,535.88 | 2019-2025 | Abilify Mycite, Rexulti, Nuedexta |
| Takeda Pharmaceuticals U.S.A., INC. | $1,090.79 | 2019-2025 | Trintellix |
| Corium, LLC | $1,058.20 | 2022-2025 | Azstarys |
| Axsome Therapeutics, INC. | $1,024.50 | 2022-2025 | Auvelity, Sunosi |
| Neurocrine Biosciences, INC. | $909.01 | 2019-2025 | Ingrezza |
| Lundbeck LLC | $740.03 | 2019-2025 | Rexulti |
| Allergan, INC. | $694.05 | 2019-2020 | |
| Bausch Health US, LLC | $641.30 | 2019-2025 | Aplenzin, Wellbutrin |
| Alkermes, INC. | $604.26 | 2021-2025 | Aristada, Lybalvi |
| Ironshore Pharmaceuticals INC. | $466.77 | 2019-2024 | Jornay Pm |
| Janssen Pharmaceuticals, INC | $461.99 | 2020-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Sunovion Pharmaceuticals INC. | $376.28 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $335.86 | 2021-2023 | Belsomra |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $324.94 | 2022-2025 | Quviviq, Quviviq |
| Supernus Pharmaceuticals, INC. | $320.62 | 2021-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $299.92 | 2019-2025 | Dyanavel Xr |
| Vanda Pharmaceuticals INC. | $283.02 | 2019-2025 | Fanapt |
| Collegium Pharmaceutical, INC. | $221.43 | 2025 | Jornay Pm |
| Teva Pharmaceuticals USA, INC. | $201.99 | 2019-2025 | Austedo Xr |
| Jazz Pharmaceuticals INC. | $192.86 | 2020-2022 | |
| Neuronetics, INC. | $185.37 | 2019 | |
| Adlon Therapeutics L.P. | $138.61 | 2019-2021 | |
| Eisai INC. | $122.12 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $114.40 | 2025 | Cobenfy |
| Harmony Biosciences LLC | $108.77 | 2024-2025 | |
| Vertical Pharmaceuticals, LLC | $98.29 | 2019-2025 | Relexxii |
| Neos Therapeutics, LP | $67.19 | 2019-2023 | Adzenys Xr-Odt |
| Avanir Pharmaceuticals, INC. | $62.35 | 2021-2022 | |
| Almatica Pharma LLC | $47.31 | 2022 | |
| Shire North American Group INC | $31.15 | 2019 | |
| Sage Therapeutics, LLC | $18.13 | 2024 | |
| Alfasigma USA, INC. | $11.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Wind listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.